Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Oncology

Advertisement

Advertisement

Featured

Gareth Morgan, MD, NYU Langone Medical Center
Conference Coverage
Assessing the Strength of Minimal Residual Disease Testing for Patients With Multiple Myeloma
04/19/2024

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in...
04/19/2024
Oncology
David Siegel, MD, PhD, Hackensack Meridian Health
Conference Coverage
Exploring the Role of Stem Cell Transplant for Patients With Myeloma Older Than 65
04/19/2024

Featuring David Siegel, MD, PhD

Featuring David Siegel, MD, PhD ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates &...
04/19/2024
Oncology
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma
04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Brea Lipe, University of Rochester Medical Center
Conference Coverage
Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?
04/16/2024

Featuring Brea Lipe, MD

Featuring Brea Lipe, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Thomas Powles, MD, MBBS, Barts Cancer Institute
Videos
Enfortumab Vedotin and Pembrolizumab Among Patients With Advanced Urothelial Cancer in the First-Line Setting
04/11/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...
Thomas Powles, MBBS, MD, discusses results from the phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab improved survival outcomes among patients with previously untreated advanced urothelial carcinoma.
Thomas Powles, MBBS, MD, discusses results from the phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab improved survival outcomes among patients with previously untreated advanced urothelial carcinoma.
Thomas Powles, MBBS, MD,...
04/11/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS
04/10/2024

Featuring Aditi Shastri, MD

Featuring Aditi Shastri, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates &...
04/10/2024
Oncology
Joseph Mikhael, MD, MEd, FRCPC, FACP
Conference Coverage
Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?
04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates &...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment
04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates &...
04/09/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
04/09/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
04/09/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network

Advertisement

Advertisement

Advertisement

Insights From the ESMO Congress

Conference Coverage
Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma
11/22/2023

Stephanie Holland 

Stephanie Holland 
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Quiz
Tisotumab Vedotin for Cervical Cancer
11/21/2023
11/21/2023
Oncology
Juergen C. Becker, MD, PhD
Conference Coverage
Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma
11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD,...
11/20/2023
Oncology
Arlene Siefker-Radtke, MD, MD Anderson Cancer Center
Videos
Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma
11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD,...
11/16/2023
Oncology
Sara Lonardi, MD, Veneto Institute of Oncology
Videos
Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer
11/16/2023

Featuring Sara Lonardi, MD

Featuring Sara Lonardi, MD
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results...
11/16/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer
11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Oleg Gluz, MD
Conference Coverage
Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer
11/10/2023

Featuring Oleg Gluz, MD

Featuring Oleg Gluz, MD
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical...
11/10/2023
Oncology
News
Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy
11/10/2023
Allison Casey
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3...
11/10/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Allison Casey
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone...
11/10/2023
Oncology

Insights From the ASCO Annual Meeting

Stefan Knop, MD
Videos
Triplet vs Quadruplet Regimen for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
08/28/2023

Featuring Stefan Knop, MD

Featuring Stefan Knop, MD
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Stefan Knop, MD, presents...
08/28/2023
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
Mirvetuximab Soravtansine Improved Overall Survival for Patients With Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer
07/27/2023
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting,...
07/27/2023
Oncology
Reid Merryman, MD
Videos
Epcoritamab Plus Rituximab and Lenalidomide Regimen Demonstrates High Response Rates Among Patients With High-Risk Follicular Lymphoma
07/19/2023

Featuring Reid Merryman, MD

Featuring Reid Merryman, MD
At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.
At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.
At the 2023 ASCO meeting, Reid...
07/19/2023
Oncology
Conference Coverage
Sintilimab Added to Chemoradiotherapy Improved Event-Free Survival in High-Risk Nasopharyngeal Carcinoma
07/18/2023

Amber Denham

Amber Denham
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to...
07/18/2023
Oncology
Tsz Lun Yeung, MD
Videos
Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer
07/18/2023

Featuring Tsz Lun Yeung, MD

Featuring Tsz Lun Yeung, MD
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting,...
07/18/2023
Oncology
Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Videos
Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
07/17/2023

Featuring Paul Paik, MD

Featuring Paul Paik, MD
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer
07/17/2023

Featuring Ticiana Leal, MD 

Featuring Ticiana Leal, MD 
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Tycel Phillips, MD
Videos
Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL
06/26/2023

Featuring Tycel Phillips, MD

Featuring Tycel Phillips, MD
Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.
Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.
Tycel Phillips, MD, presented...
06/26/2023
Oncology
Carlotta Antoniotti, MD, PhD, University of Pisa
Videos
Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-Line Setting
06/22/2023

Featuring Carlotta Antoniotti, MD, PhD

Featuring Carlotta Antoniotti, MD, Ph...
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting,...
06/22/2023
Oncology
Kerry Rogers, MD
Videos
Ibrutinib Dose Adjustments in the Frontline Treatment of Patients With CLL
06/22/2023

Featuring Kerry Anne Rogers, MD

Featuring Kerry Anne Rogers, MD ...
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
At the 2023 ASCO Annual Meeting...
06/22/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Live Meetings

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/19/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase...
04/19/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma
04/19/2024

Jordan Kadish 

Jordan Kadish 
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an...
04/19/2024
Oncology
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology
News
Venetoclax With Low-Dose Cytarabine Demonstrates Efficacy, Tolerability for Patients With AML at First MRD or Oligoblastic Relapse
04/18/2024

Amber Denham

Amber Denham
Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.
Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.
Venetoclax with low-dose...
04/18/2024
Oncology
News
Adjuvant Alectinib Significantly Improved Disease-Free Survival Among Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/18/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.
According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.
According to results from the...
04/18/2024
Oncology
News
Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
04/18/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the...
04/18/2024
Oncology
News
Pazopanib Failed to Improve Long-Term Survival Results Among Patients With Metastatic Renal Cell Carcinoma Post-Metastasectomy at High Risk of Recurrence
04/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the ECOG-ACRIN E2810 study, pazopanib did not improve long-term disease-free survival or overall survival among patients with metastatic renal cell carcinoma with no evidence of disease after metastasectomy at high...
According to results from the...
04/16/2024
Oncology
News
Atezolizumab Plus Cabozantinib Failed to Improve Survival Among Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 CONTACT-01 trial demonstrated that atezolizumab plus cabozantinib did not improve OS or PFS compared to docetaxel among patients with metastatic NSCLC who experienced disease progression after prior treatment.
Results from the phase 3 CONTACT-01 trial demonstrated that atezolizumab plus cabozantinib did not improve OS or PFS compared to docetaxel among patients with metastatic NSCLC who experienced disease progression after prior treatment.
Results from the phase 3...
04/09/2024
Oncology
News
Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL...
04/09/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement